Discovery Timeline
The development of ProdromeNeuro™ is built on an extensive foundation of research and discovery spanning over 20 years :
2007
Plasmalogens discovered to be decreased in Alzheimer’s disease.
2007
First targeted plasmalogen precursor (PPI‑1005) invented.
2008
Plasmalogen precursor PPI-1011 is invented (the drug version of PPI-1005)
2007
Definitive plasmalogen deficiency paper in Alzheimer’s disease.
2011
Oral bioavailability and metabolism of PPI-1011
2015-2016
Animal neurodegeneration reversal studies
2015-2016
Show that changes in phosphatidylcholine levels in Alzheimer's disease and dementia are caused by impaired peroxisomal function
2019
APOE4 × plasmalogen epidemiology
2019
Launches ProdromeNeuro — the first commercially available plasmalogen precursor supplement, based on DHA-AAG technology filed in 2008 (US 9,334,235 B2, granted 2016)
2020
ADNI confirmatory data
2021
Published Breaking Alzheimers
2022
Human brain post-mortem data on relationship between brain plasmalogen levels and cognition
2022
Published first human trial on plasmalogen precursors
2026